Asia-Pacific Healthcare Investment Solid Despite Global Worries
Executive Summary
Solid fundamentals in the Asia-Pacific healthcare market are continuing to attract significant investment and M&A activity with no signs of a slowdown, despite fears over China’s economic growth and negative factors in the wider global economy. Medtech, digital health and health services are all set to benefit, experts say.
You may also be interested in...
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
Re-Listing Still The Best Option For Chinese Life Sciences Firms?
There has been a trend for US-listed Chinese life sciences and health care companies to go private and eventually relist back home. But this process is not only becoming increasingly cumbersome, there is a lot more to worry about than just getting a higher valuation, insiders tell PharmAsia News.
Caution Advised In China’s Digital Dash Into Healthcare’s Future
China’s digital healthcare market is set to expand massively and reach $110bn by 2020, disrupting the industry, creating fresh opportunities and casting aside those who don’t keep up with the times. However, experts caution that digital solutions are no panacea unless they have real patient-centered value.